CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
of Best Available Therapy (BAT) for treatment-resistant relapsing multiple sclerosis (MS). Participants will be randomized...
Phase 3
New York, New York, United States and 19 other locations
due to cancer or other illnesses such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson'...
Phase 2
New York, New York, United States and 7 other locations
To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS...
Phase 3
New Brunswick, New Jersey, United States and 72 other locations
In this study, researchers will learn more about a study drug called BIIB091 in participants with MS who may be experiencing relapses. It is...
Phase 2
Teaneck, New Jersey, United States and 76 other locations
of nasal foralumab in patients with non-active secondary progressive multiple sclerosis (SPMS).The primary objectives that this stu...
Phase 2
New York, New York, United States and 6 other locations
(maintenance) in people with systemic lupus erythematosus (lupus), infantile spasms, adults with acute relapses or flares of multiple sclerosis...
Phase 2
Palisades Park, New Jersey, United States of America and 2 other locations
This study aims to examine the efficacy and safety of obexelimab in participants with relapsing multiple sclerosis...
Phase 2
Teaneck, New Jersey, United States of America and 46 other locations
This double-blind, double-dummy study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with...
Phase 3
New Brunswick, New Jersey, United States and 105 other locations
This study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofat...
Phase 4
Livingston, New Jersey, United States and 42 other locations
The main objective of the study is to determine the recommended phase 2 dose (RP2D) of Azercabtagene zapreleucel (azer-cel).
Phase 1
New York, New York, United States and 4 other locations
Clinical trials
Research sites
Resources
Legal